Sugi Predict

Sugi Predict / Compounds / SCHEMBL1085042

SCHEMBL1085042

SCHEMBL1085042

COC(=O)c1c(C)cc(Cl)nc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.50
▸ MEN1 O00255 2/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ CYP3A4 P08684 2/20 0.49
▸ ACHE P22303 1/20 0.49
▸ TAAR1 Q96RJ0 1/20 0.48
▸ HPGD P15428 2/20 0.46
▸ KDM4E B2RXH2 4/20 0.44
▸ POLB P06746 3/20 0.44
▸ HSD17B10 Q99714 2/20 0.44
▸ CASP1 P29466 1/20 0.44
▸ PLA2G2A P14555 1/20 0.40
▸ GLA P06280 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.39
▸ CA12 O43570 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30430258 1.00 ALDH1A1 (0.50) ALDH1A1MEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL25151051 0.87 CYP3A4 (0.47) ALDH1A1MEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL18786786 0.86 CYP3A4 (0.46) ALDH1A1MEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL24773237 0.86 CYP3A4 (0.50) ALDH1A1MEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL22689984 0.85 ALDH1A1 (0.65) ALDH1A1MEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL1710208 0.85 KDM4E (0.44) ALDH1A1MEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL1085064 0.84 POLB (0.47) ALDH1A1MEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL25343847 0.84 KDM4E (0.54) ALDH1A1MEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL24175026 0.84 CYP3A4 (0.51) ALDH1A1MEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL14660349 0.82 ALDH1A1 (0.43) ALDH1A1MEN1KMT2ASMN1; SMN2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4313981-B1 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS PFIZER (US) 2026-02-25 — — EP disclosed
US-20250361238-A1 1,4-DIPHENYL-1H-INDAZOLE AND 1-PYRIDIN-2-YL-4-PHENYL-1H-INDAZOLE DERIVATIVES AS PD-1/PD-L1 MODULATORS FOR THE TREATMENT OF CANCER SOPONPONG JAKAPUN (TH) 2025-11-27 — — US disclosed
EP-3952870-B1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS NANJING ZENSHINE PHARMACEUTICALS CO LTD (CN) 2025-09-24 — — EP disclosed
US-20250263411-A1 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS PFIZER INC. (US) 2025-08-21 — — US disclosed
CN-120020134-A Heterocyclic carbonyl derivative regulator, preparation method and application thereof 江苏豪森药业集团有限公司 2025-05-20 — — CN disclosed
CN-119768404-A Heteroaryl substituted pyridopyrrolidone derivatives, pharmaceutical compositions and uses thereof 上海海雁医药科技有限公司 2025-04-04 — — CN disclosed
EP-4524135-A1 KINESIN KIF18A INHIBITOR AND USE THEREOF Shanghai Apeiron Therapeutics Company Limited (CN) 2025-03-19 — — EP disclosed
CN-119638687-A Aromatic heterocyclic pyrrolidones and uses thereof 杭州百新生物医药科技有限公司 2025-03-18 — — CN disclosed
WO-2024220626-A1 SMALL MOLECULE MODULATORS OF OGG1 AZKARRA THERAPEUTICS, INC. (US) 2024-10-24 — — WO disclosed
CN-117642392-A Preparation and application of compounds with immunoregulation function 上海轶诺药业有限公司 2024-03-01 — — CN disclosed
US-20100298221-A1 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-11-25 — — US disclosed
US-20100298221-A1 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-11-25 — — US disclosed
US-20100298221-A1 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-11-25 — — US disclosed
CN-101801952-A N-heterocyclic biaryl carboxamides as ccr receptor antagonists HOFFMANN LA ROCHE 2010-08-11 — — CN disclosed
EP-2205583-A2 N-HETEROCYCLIC BIARYL CARBOXAMIDES AS CCR RECEPTOR ANTAGONISTS F. Hoffmann-Roche AG (CH) 2010-07-14 — — EP disclosed
US-20090318467-A1 NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-12-24 — — US disclosed
WO-2009153182-A1 NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-12-23 — — WO disclosed
WO-2009043747-A2 N-HETEROCYCLIC BIARYL CARBOXAMIDES AS CCR RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-04-09 — — WO disclosed
US-20090048238-A1 NOVEL BIARYL DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-02-19 — — US disclosed
WO-2008031501-A2 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298221-A1 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF NAPRT, PNPO, FABP3 ALDH1A1 1855/4885MEN1 4297/4885KMT2A 1678/4885
US-20090048238-A1 NOVEL BIARYL DERIVATIVES CCR3, CCRL2, CCR2 ALDH1A1 1202/4885MEN1 4348/4885KMT2A 3593/4885
US-20090318467-A1 NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES CCR3, CCR2, CCR1 ALDH1A1 1982/4885MEN1 3975/4885KMT2A 1597/4885
US-20250361238-A1 1,4-DIPHENYL-1H-INDAZOLE AND 1-PYRIDIN-2-YL-4-PHENYL-1H-INDAZOLE DERIVATIVES AS PD-1/PD-L1 MODULATORS FOR THE TREATMENT OF CANCER PDCD1, CD274, PDCD1LG2 ALDH1A1 36/4885MEN1 2605/4885KMT2A 2449/4885
US-20250263411-A1 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS NRAS, KRAS, BRAF ALDH1A1 1249/4885MEN1 1047/4885KMT2A 250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.